Systemic Tacrolimus Attenuates Peri-Implant Capsule Formation and Inflammatory/Fibrotic Signaling in a Rat Silicone Implant Model
Aesthetic Plastic Surgery · 2026-10 · 50 (20) · 8293-8301
DOI: 10.1007/s00266-026-05918-9 ↗At a glance
Journal article in Aesthetic Plastic Surgery, published online on 2026-07-28. Written by Hyung Bae Kim and 3 co-authors. Institution: Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Sonpa-gu, Seoul, …. Major MEDLINE topics: Tacrolimus, Immunosuppressive Agents, Breast Implants, Implant Capsular Contracture. 20 references. Funded by: Asan Institute for Life Sciences, Asan Medical Center.
Abstract (original language)
Background
Capsule formation in contact with silicone implants may vary according to the administration of systemic immunosuppressive drugs.
Methods
A total of 18 Sprague-Dawley rats that underwent premuscular plane silicone implant insertion were divided into three groups as follows: Group 1, untreated negative control ( n = 6); Group 2, treated with tacrolimus ( n = 6); and Group 3, treated with dexamethasone as a positive control ( n = 6). At 3 months after surgery, the histology and immunochemistry of the capsule tissues were analyzed.
Results
Systemic administration of dexamethasone and tacrolimus successfully reduced capsule thickness and inflammatory marker levels. The aggregation of CD3 (T lymphocytes)- and CD68 (histiocytes)-positive cells around the capsule also reduced.
Conclusions
This study aimed to evaluate whether systemic immunosuppression with tacrolimus modulates peri-implant capsule formation and key inflammatory/fibrotic pathways in a rat silicone implant model. We focused on histologic capsule thickness and immunohistochemical markers representing innate/adaptive immune activation and myofibroblast-driven fibrosis as surrogate measures of early periprosthetic tissue remodeling. No Level Assigned This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Sonpa-gu, Seoul, 138-736, Republic of Korea.
- Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-dong, Sonpa-gu, Seoul, 138-736, Republic of Korea. jinsupp@amc.seoul.kr.
Funding
- Asan Institute for Life Sciences, Asan Medical Center
Cite
APA
Kim, H. B., Lee, N., Han, H. H., & Eom, J. S. (2026). Systemic Tacrolimus Attenuates Peri-Implant Capsule Formation and Inflammatory/Fibrotic Signaling in a Rat Silicone Implant Model. Aesthetic Plastic Surgery, 50(20), 8293-8301. https://doi.org/10.1007/s00266-026-05918-9
Vancouver
Kim HB, Lee N, Han HH, Eom JS. Systemic Tacrolimus Attenuates Peri-Implant Capsule Formation and Inflammatory/Fibrotic Signaling in a Rat Silicone Implant Model. Aesthetic Plastic Surgery. 2026;50(20):8293-8301. doi:10.1007/s00266-026-05918-9
BibTeX
@article{Kim2026,
author = {Kim, Hyung Bae and Lee, Nara and Han, Hyun Ho and Eom, Jin Sup},
title = {Systemic Tacrolimus Attenuates Peri-Implant Capsule Formation and Inflammatory/Fibrotic Signaling in a Rat Silicone Implant Model},
journal = {Aesthetic Plastic Surgery},
year = {2026},
volume = {50},
number = {20},
pages = {8293--8301},
doi = {10.1007/s00266-026-05918-9}
}
EUVIMED